Rehan, Shahid
Tranter, Dale
Sharp, Phillip P. http://orcid.org/0000-0003-4416-2303
Craven, Gregory B. http://orcid.org/0000-0003-3414-8348
Lowe, Eric
Anderl, Janet L.
Muchamuel, Tony
Abrishami, Vahid http://orcid.org/0000-0002-3772-7663
Kuivanen, Suvi
Wenzell, Nicole A.
Jennings, Andy
Kalyanaraman, Chakrapani
Strandin, Tomas
Javanainen, Matti http://orcid.org/0000-0003-4858-364X
Vapalahti, Olli http://orcid.org/0000-0003-2270-6824
Jacobson, Matthew P. http://orcid.org/0000-0001-6262-655X
McMinn, Dustin
Kirk, Christopher J.
Huiskonen, Juha T. http://orcid.org/0000-0002-0348-7323
Taunton, Jack http://orcid.org/0000-0002-9627-5898
Paavilainen, Ville O. http://orcid.org/0000-0002-3160-7767
Funding for this research was provided by:
Academy of Finland (338160, 314669, 338836, 314672)
Emil Aaltosen Säätiö
Sigrid Juséliuksen Säätiö
Jane ja Aatos Erkon Säätiö
Article History
Received: 3 June 2022
Accepted: 6 April 2023
First Online: 11 May 2023
Competing interests
: E.L., J.A., T.M. and C.J.K. are employees and shareholders of Kezar Life Sciences. D.M. is a shareholder of Kezar Life Sciences. J.T. is a founder of Global Blood Therapeutics, Kezar Life Sciences, Cedilla Therapeutics and Terremoto Biosciences, and is a scientific advisor to Entos. The remaining authors declare no competing interests.